Symbols

ESPR

Esperion·NASDAQ

--(--)

ESPR fundamentals

ESPR Q4 2025 Earnings

Esperion (ESPR) released its earnings on Mar 10, 2026: revenue was 168.45M (YoY +143.73%), beat estimates; EPS was 0.22 (YoY +300.00%), missed estimates.

Revenue / YoY

168.45M

+143.73%

EPS / YoY

0.22

+300.00%

Report date

Mar 10, 2026

ESPR Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 U.S. net product revenue up 38% YoY, collaboration revenue surging 232% due to Otsuka milestone.
Strategic Acquisition: $4+ billion heart failure market entry via Enbumyst, closing Q2 2026 with immediate cross-selling synergies.
Pipeline Breakthrough: ESP-2001 advancing to IND, targeting PSC with no approved therapies.
Global Expansion: Japan launch of NEXLETOL exceeds expectations, treating over 700,000 patients globally.
Financial Strength: $167.9 million cash, 2026 operating expenses guided at $225-$255 million, supporting aggressive growth strategy.

Earnings

EPS

Revenue

Revenue & Expenses

ESPR has released its 2025 Q4 earnings report, with revenue of 168.45M, reflecting a YoY change of 143.73%, and net profit of 61.83M, showing a YoY change of 390.04%. The Sankey diagram below clearly presents ESPR's revenue sources and cost distribution.

Key Indicators

Esperion (ESPR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Esperion (ESPR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Esperion (ESPR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Esperion (ESPR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown